Modulation of the gait deficit in arthritic rats by infusions of muscimol and bicuculline

Shabana U. Simjee, Barbara J. Pleuvry, Paul Coulthard

    Research output: Contribution to journalArticlepeer-review


    Gait analysis in the adjuvant-induced arthritic rat model of chronic pain was used to examine the role of GABAA receptors in the development of pain. Drug solutions were administered continuously at 5±0.75 μl/h for 14 days via Alzet® osmotic pumps (2ML2) placed under the skin of the back. The GABAA receptor agonist, muscimol, produces a dose-dependent reversal of the gait deficits seen in arthritic rats without reducing the tibiotarsal joints inflammatory edema or the histological picture of joint erosion and inflammation. The higher infusion rate for muscimol, 20 μg/h, caused the gait for the arthritic rats to be indistinguishable from that of normal non-arthritic rats. In normal, non-arthritic rats, muscimol did not show any effect on gait. The GABAA receptor antagonist bicuculline showed small but significant exacerbation of stride length (P
    Original languageEnglish
    Pages (from-to)453-460
    Number of pages7
    Issue number3
    Publication statusPublished - Jun 2004


    • Arthritis
    • Bicuculline
    • Chronic pain
    • Muscimol


    Dive into the research topics of 'Modulation of the gait deficit in arthritic rats by infusions of muscimol and bicuculline'. Together they form a unique fingerprint.

    Cite this